TY - JOUR
T1 - Meningeal dendritic cells drive neuropathic pain through elevation of the kynurenine metabolic pathway in mice
AU - Maganin, Alexandre G.
AU - Souza, Guilherme R.
AU - Fonseca, Miriam D.
AU - Lopes, Alexandre H.
AU - Guimarães, Rafaela M.
AU - Dagostin, André
AU - Cecilio, Nerry T.
AU - Mendes, Atlante S.
AU - Gonçalves, William A.
AU - Silva, Conceição E.A.
AU - Gomes, Francisco Isaac Fernandes
AU - Mauriz Marques, Lucas M.
AU - Silva, Rangel L.
AU - Arruda, Letícia M.
AU - Santana, Denis A.
AU - Lemos, Henrique
AU - Huang, Lei
AU - Davoli-Ferreira, Marcela
AU - Santana-Coelho, Danielle
AU - Sant'Anna, Morena B.
AU - Kusuda, Ricardo
AU - Talbot, Jhimmy
AU - Pacholczyk, Gabriela
AU - Buqui, Gabriela A.
AU - Lopes, Norberto P.
AU - Alves-Filho, Jose C.
AU - Leão, Ricardo M.
AU - O'Connor, Jason C.
AU - Cunha, Fernando Q.
AU - Mellor, Andrew
AU - Cunha, Thiago M.
N1 - Publisher Copyright:
Copyright: © 2022, Maganin et al.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Neuropathic pain is one of the most important clinical consequences of injury to the somatosensory system. Nevertheless, the critical pathophysiological mechanisms involved in neuropathic pain development are poorly understood. In this study, we found that neuropathic pain is abrogated when the kynurenine metabolic pathway (KYNPATH) initiated by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is ablated pharmacologically or genetically. Mechanistically, it was found that IDO1-expressing dendritic cells (DCs) accumulated in the dorsal root leptomeninges and led to an increase in kynurenine levels in the spinal cord. In the spinal cord, kynurenine was metabolized by kynurenine-3-monooxygenase-expressing astrocytes into the pronociceptive metabolite 3-hydroxykynurenine. Ultimately, 3-hydroxyanthranilate 3,4-dioxygenase-derived quinolinic acid formed in the final step of the canonical KYNPATH was also involved in neuropathic pain development through the activation of the glutamatergic N-methyl-D-aspartate receptor. In conclusion, these data revealed a role for DCs driving neuropathic pain development through elevation of the KYNPATH. This paradigm offers potential new targets for drug development against this type of chronic pain.
AB - Neuropathic pain is one of the most important clinical consequences of injury to the somatosensory system. Nevertheless, the critical pathophysiological mechanisms involved in neuropathic pain development are poorly understood. In this study, we found that neuropathic pain is abrogated when the kynurenine metabolic pathway (KYNPATH) initiated by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is ablated pharmacologically or genetically. Mechanistically, it was found that IDO1-expressing dendritic cells (DCs) accumulated in the dorsal root leptomeninges and led to an increase in kynurenine levels in the spinal cord. In the spinal cord, kynurenine was metabolized by kynurenine-3-monooxygenase-expressing astrocytes into the pronociceptive metabolite 3-hydroxykynurenine. Ultimately, 3-hydroxyanthranilate 3,4-dioxygenase-derived quinolinic acid formed in the final step of the canonical KYNPATH was also involved in neuropathic pain development through the activation of the glutamatergic N-methyl-D-aspartate receptor. In conclusion, these data revealed a role for DCs driving neuropathic pain development through elevation of the KYNPATH. This paradigm offers potential new targets for drug development against this type of chronic pain.
UR - http://www.scopus.com/inward/record.url?scp=85143180279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143180279&partnerID=8YFLogxK
U2 - 10.1172/JCI153805
DO - 10.1172/JCI153805
M3 - Article
C2 - 36227694
AN - SCOPUS:85143180279
SN - 0021-9738
VL - 132
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 23
M1 - e153805
ER -